Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

Octapharma

Status and phase

Completed

Phase 3

Conditions

Congenital Fibrinogen Deficiency

Treatments

Drug: Octafibrin

Study type

Interventional

Funder types

Industry

Identifiers

NCT02267226

FORMA-02

Details and patient eligibility

About

The purpose of the study is to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency.

Enrollment

25 patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged ≥12 years (only 18 and above in Russia)
Documented diagnosis of congenital fibrinogen deficiency, expected to require on-demand treatment for bleeding or surgical prophylaxis:
Fibrinogen deficiency manifested as afibrinogenaemia or severe hypofibrinogenaemia.
Historical plasma fibrinogen activity of <50 mg/dL or levels below the limit of detection of the local assay method.
Expected to have an acute bleeding episode (spontaneous or after trauma) or planning to undergo elective surgery.
Informed consent signed by the subject or legal guardian.

Exclusion criteria

Life expectancy <6 months.
Bleeding disorder other than congenital fibrinogen deficiency, including dysfibrinogenaemia.
Prophylactic treatment with a fibrinogen concentrate.

Treatment with:

Any fibrinogen concentrate or other fibrinogen-containing blood product within 2 weeks prior to start of treatment for the bleeding episode or surgery.
Any coagulation-active drug (i.e., non-steroidal anti-inflammatory drugs, warfarin, coumarin derivatives, platelet aggregation inhibitors) within 1 week prior to start of treatment for the bleeding episode or surgery, or as a planned or expected medication during the time period from Day 1 until 24 hours (i.e., 1 day) after the last Octafibrin infusion.

Presence or history of:

Hypersensitivity to study medication.
Deep vein thrombosis or pulmonary embolism within 1 year prior to start of treatment for the bleeding episode or surgery.
Arterial thrombosis within 1 year prior to start of treatment for the bleeding episode or surgery
Hypersensitivity to human plasma proteins.
Oesophageal varicose bleeding.
End-stage liver disease (i.e., Child-Pugh score B or C).

Pregnant women within the first 20 weeks of gestation.

Currently breast-feeding.

Known positive HIV infection with a viral load >200 particles/μL or >400,000 copies/mL.

Polytrauma 1 year prior to start of treatment for the bleeding episode or surgery.

Diagnosis or suspicion of a neutralizing anti-fibrinogen inhibitor currently or any time in the past.

Acute or chronic medical condition which may, in the opinion of investigator, affect the conduct of the study, including

Subjects receiving immune-modulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to >10 mg/day), or similar drugs at study start.
Subjects having evidence or a history (within the previous 12 months) of abuse of any licit or illicit drug substance.

Participation in another interventional clinical study currently or during the past 4 weeks.